Avid selects MilliporeSigma to meet single-use trend

By Flora Southey

- Last updated on GMT

Avid Bioservices has installed two MilliporeSigma Mobius 2,000L single-use bioreactors at its facility in Tustin, California, US.

Avid Bioservices – a subsidiary of Peregrine Pharmaceuticals – said it reviewed several suppliers before choosing MilliporeSigma’s technology.

“Avid ran a competitive process in considering which single-use bioreactors to install in our Myford​ [Myford Road, Tustin] facility,” ​said president Roger Lias.

“While we carefully reviewed a number of single-use bioreactor options, we chose the MilliporeSigma Mobius 2,000L single-use bioreactor system because it offers technical and ease of use advantages over competing single-use systems,” ​he told us. 

The contract development and manufacturing organisation (CDMO) did not disclose the purchase price.

New business

Avid said it opted for single-use bioreactors in response to growing demand for larger scale, disposable technology.

“This enhancement of our capabilities is just the latest step in our ongoing efforts to expand and diversify our customer base,” ​said Lias.

The firm told us a percentage of bioreactor capacity had already been allocated to customers.

“With not all capacity currently accounted for we are able to offer prospective new clients a unique short-term opportunity to obtain capacity in a cutting-edge commercial facility,” ​Lias told us.

Avid said it has room to house one additional 2,000L bioreactor at its Myford Road facility.

A move to single-use?

Lias said single-use technology is a growing trend in the biopharmaceutical industry.

“We believe that there is a clear movement within the industry toward single-use, fully disposable manufacturing” ​he told us.

Disposable bioreactors improves turnaround times, reduces product cross-contamination risk and decreases capital costs, he said.

“Single-use manufacturing technology helps accelerate moving molecules to market, improves productivity and ensures supply continuity,” ​he added.

Related news

Show more

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us


View more